Olympus Corporation

Japanese Foundation for Cancer Research

Japan Breast Cancer Research Group

Futoshi Akiyama

Seigo Nakamura

Tatsuki Yamada

Masakazu Toi

Hitoshi Tsuda

Rie Horii

Hiroji Iwata

Katsumasa Kuroi

Shinji Ohno

Norikazu Masuda

Kenjiro Aogi

Nobuaki Sato

Masafumi Kurosumi

A microscope system includes a pigment amount calculating unit, a cell component identification processing unit, a target molecule expression portion extraction unit, a cell variant setting unit, a cell variant classification determining unit, and a display image generating unit. The pigment amount calculating unit calculates a pigment amount of a molecule target pigment for each pixel of a VS image. The cell component identification processing unit identifies a cell component based on the pigment amount. The target molecule expression portion extraction unit extracts expression portions of target molecules in the area of the cell component. The cell variant setting unit sets a cell variant including a combination of presence/absence of expressions of target molecules. The cell variant classification determining unit classifies a cell area in the VS image into a cell variant based on the combination of the expression portions of the target molecules included in the cell area.

Microscope system, specimen observing method, and computer-readable recording medium

An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Method for the administration of anti-cancer drugs

Growing community of inventors

Tokyo, Japan

Futoshi Akiyama